Last reviewed · How we verify
R2-Total targeted treatment with azithromycin
R2-Total targeted treatment with azithromycin, marketed by Lihir Medical Centre, holds a position in the pharmaceutical market with its key composition patent expiring in 2028. The drug's primary strength lies in its unique mechanism of action, which differentiates it from other treatments. The primary risk is the lack of reported revenue and key trial results, which may impact investor confidence and market adoption.
At a glance
| Generic name | R2-Total targeted treatment with azithromycin |
|---|---|
| Also known as | R2-TTT |
| Sponsor | Lihir Medical Centre |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: